ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CDLX Cardlytics Inc

3.82
-0.06 (-1.55%)
28 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cardlytics Inc NASDAQ:CDLX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.06 -1.55% 3.82 3.81 3.90 4.0291 3.7642 3.81 630,335 01:00:00

Form 8-K - Current report

03/10/2024 9:03pm

Edgar (US Regulatory)


0001666071false00016660712024-09-302024-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 30, 2024
 
cardlytics_logoa30.jpg
CARDLYTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3838626-3039436
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
675 Ponce de Leon Avenue NE, Suite 6000AtlantaGeorgia30308
(Address of principal executive offices, including zip code)
(888)798-5802
(Registrant's telephone, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each classTrading symbolName of each exchange on which registered
Common StockCDLXThe Nasdaq Stock Market LLC
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




ITEM 1.01 Entry into a Material Definitive Agreement
On September 30, 2024, Cardlytics, Inc. (the “Company”) entered into an amended and restated loan and security agreement (the “Agreement”) by and among the Company, certain subsidiaries of the Company named therein and Banc of California, N.A (“Lender”), formerly known as Pacific Western Bank. The Agreement amends and restates the original Loan and Security Agreement, dated as of May 21, 2018, by and between Company and Lender, as subsequently amended (the “Existing Agreement”). The Agreement consolidates the Existing Agreement and all subsequent amendments thereto into a single document. Except for immaterial changes, the terms of the Agreement are consistent with the terms of the Existing Agreement, as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the Agreement, which the Company intends to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 Cardlytics, Inc.
   
Date:October 3, 2024By:/s/ Alexis DeSieno
  Alexis DeSieno
  
Chief Financial Officer
(Principal Financial and Accounting Officer)


v3.24.3
Document and Entity Information
Sep. 30, 2024
Entity Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 30, 2024
Entity Registrant Name CARDLYTICS, INC.
Entity Central Index Key 0001666071
Entity Incorporation, State or Country Code DE
Entity File Number 001-38386
Entity Tax Identification Number 26-3039436
Entity Address, Address Line One 675 Ponce de Leon Avenue NE, Suite 6000
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30308
City Area Code (888)
Local Phone Number 798-5802
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Title of 12(b) Security Common Stock
Security Exchange Name NASDAQ
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Registrant Name CDLX

1 Year Cardlytics Chart

1 Year Cardlytics Chart

1 Month Cardlytics Chart

1 Month Cardlytics Chart

Your Recent History

Delayed Upgrade Clock